FDA Approves Glaukos' New Drug Application for iDose TR
By Dean Seal
Glaukos said federal regulators have approved a new drug application for iDose TR, a treatment for ocular hypertension and open-angle glaucoma.
The ophthalmic medical technology and pharmaceutical company said Thursday morning that the Food and Drug Administration approved the application for a single administration per eye of iDose TR for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Glaukos said iDose TR is designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.
The approval is based on two pivotal Phase 3 trials that successfully achieved their primary efficacy endpoints through three months and demonstrated a favorable tolerability and safety profile through 12 months.
Glaukos intends to start initial commercial launch activities for iDose TR in the latter part of the first quarter of 2024.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 14, 2023 07:49 ET (12:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results